BioXcel Therapeutics receives permanent J-Code for IGALMI

BioXcel Therapeutics announced that the Centers for Medicare & Medicaid Services, CMS, has issued a permanent and product-specific J-Code for IGALMI sublingual film, which is approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults1,2. Under the Healthcare Common Procedure Coding System, HCPCS, process, the IGALMI J-Code J1105 will become effective January 1, 2024. “Beginning next year, IGALMI will be separately reimbursed under a direct and predictable J-Code for the hospital outpatient setting, which we expect will help remove economic barriers that may have impacted formulary approval decisions and product utilization to date,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “Ultimately, we believe this commercial milestone will facilitate additional patient access to this important therapeutic option for the treatment of bipolar disorder- or schizophrenia-associated agitation.”